Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women.

Author(s): Provinciali N,  Suen C,  Dunn BK,  DeCensi A

Journal: Expert Rev Clin Pharmacol

Date: 2016 Oct

Major Program(s) or Research Group(s): BRG, PUCRG

PubMed ID: 27583816

PMC ID: not available

Abstract: INTRODUCTION: Raloxifene is an estrogen receptor modulator which competes with estrogens for binding to the estrogen receptor. Based on the results of the STAR (Study of Tamoxifen And Raloxifene) trial, raloxifene has been approved by the U.S. Food and Drug Administration for the reduction of breast cancer (BC) risk in postmenopausal women at increased risk. Areas covered: This analysis reviews the activity of raloxifene and the clinical trials for non-BC indications which led to investigate its use as BC preventive agent. We review the trial establishing its efficacy for BC prevention and the meta-analyses including different SERMs for BC prevention. Expert commentary: Compared with tamoxifen, raloxifene has shown a slightly lower efficacy in reducing BC risk and a better safety profile. Raloxifene also offers to postmenopausal women a benefit in terms of osteoporosis. Future research should investigate its use in premenopausal women and in association with other preventive agents.